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INTRODUCTION
Platelet additive solutions (PAS) have been used to store platelets since the 1980's. 1,2 PAS storage of pooled buffy coat prepared platelet concentrates have long been used in Europe. 3 The advantages of using a PAS for platelet storage are many including more plasma to meet patient needs or to fractionate into plasma-based products, reduce red cell hemolysis from ABO incompatible plasma, and reduce other adverse effects related to plasma transfusion. 4, 5 To license platelets based on post-storage radiolabeled autologous platelet viability measurements in normal subjects, the FDA requires that the lower post-storage 95% confidence limits (LCL) for platelet recoveries are
Experimental Design
Three different apheresis systems -the COBE Spectra (Spectra) and Trima Accel (Trima) (Terumo BCT, Inc., Lakewood, CO) (these systems may be collectively referred to as Terumo BCT systems), and the Haemonetics MCS+ (Haemonetics Corporation, Braintree, MA) were used. For the Haemonetics collections, the in-line white cell leukoreduction filter was removed to give the highest cell counts to stress the system while the Terumo BCT platelets were in-process leukoreduced. Haemonetics collects whole blood into a spinning centrifuge bowl and then either plasma or PAS is pumped into the bottom of the bowel to push the supernatant platelets into a collection bag for storage. 7 The Spectra has a dual-stage processing channel with the red and white cells removed in the first stage, and the platelets are concentrated in the second stage followed by transfer to a storage bag. 7 The Trima has a single-stage channel where the cells separate into layers according to specific gravity, and each component leaves by its own outlet into a storage bag. 7, 8 All collections were within the manufacturer's bag parameters for volume and total platelets per bag for 5-to 7-day plasma storage.
However, these guidelines may not be applicable to the Plasmalyte (Baxter, Deerfield, IL) extended storage studies reported here. Both the Terumo BCT and Haemonetics bags have approximately the same surface area. The apheresis platelets were separated equally into two storage bags. One bag served as the control platelets that were stored for 1, 5, or 7 days in plasma or Plasmalyte while platelets in the other bag (test platelets) were stored for 5 to 18 days in Plasmalyte, subsequently referred to as a platelet additive solution (PAS) . For some studies, the control platelets were "fresh" platelets prepared from a 43 ml whole blood sample drawn on the day the subject's stored platelets were transfused.
Platelet Radiolabeling
At the end of storage, a 43 ml aliquot from both the control and the test platelets were alternately labeled with 51 Cr or 111 In using established techniques so that, at the end of an experiment, equal numbers of each platelet type had been labeled with both isotopes, and the platelets were transfused sequentially into their donor. 9,10 Blood samples were drawn from the subject before, at 2 hours, and on days 1, 2, 3, 5, and 7 after transfusion to test for radioactivity using a Packard Model 5530 gamma counter (Downer's Grove, IL). The radiolabeled data were not corrected for potential label elution nor for possible red cell bound isotope, 9 except for the paired fresh and test platelet studies where a day 10 sample was obtained. 10 Platelet recoveries and survivals were calculated using the COST program. 11
PAS Platelets
During the Terumo BCT studies, it was possible to change the usual collection procedure to hyperconcentrate the platelets with re-suspension in PAS. 12, 13 For the Haemonetics studies, the platelets were elutriated with PAS instead of plasma during collection by sterile docking a Haemonetics bag (Effluent #692) containing PAS to the collection set. The operator would unclamp and, as appropriate, clamp the tubing to the #692 bag to permit surging with PAS. A baseline sample of the subject's plasma and For personal use only. on October 24, 2017. by guest www.bloodjournal.org From from their PAS stored platelet bag were assayed for albumin to determine the concentration of PAS versus residual plasma.
In Vitro Platelet Measurements
Platelet counts of collected products were performed on the day following collection and after storage using an ABX Hematology Analyzer (ABX Diagnostics, Irvine, CA). After storage, in vitro measurements of glucose concentration, pH at 37°C, pCO 2 , pO 2 , extent of shape change (ESC), and hypotonic shock response (HSR), 14
Annexin V binding, morphology score, 15 and mean platelet volume (MPV) were performed. Residual donor plasma was added to the PAS stored platelets to adjust the platelet count to 300,000/μl before performing the ESC and HSR measurements. 16
Statistical Methods
Summary statistics [n, mean, standard deviation (s.d.) or standard error (s.e.)] are presented for in vivo and in vitro measures of platelet quality grouped by apheresis machine and storage interval of the test platelets. In vivo measures of platelet viability, recovery and survival, from paired (test and control) studies were compared using a paired t-test. When paired with a fresh or 1-day stored control platelets, test platelets were evaluated to determine if they met FDA guidelines for post-storage platelet viability. The p values were not corrected for multiple comparisons.
RESULTS

Effect of PAS Concentration on Post-Storage Platelet Viability
Ten Haemonetics collections were stored for 7 days with PAS concentrations between 50% to 82% to determine the optimum PAS concentration. With lower PAS concentrations between 50% to 67% (n=5), recoveries averaged 65 ± 18% and survivals 5.7 ± 0.5 days, and, with higher concentrations of 77% to 82%, recoveries averaged 63 ± 11% and survivals 6.2 ± 0.7 (n=5) with no trends based on PAS concentrations. A targeted 80% PAS concentration was used for all studies.
Haemonetics Platelets
In Vivo Data
There were no significant differences between each subject's paired plasma and PAS stored platelets at 5 and 7 days of storage except for 7-day PAS recoveries which were 52± 3% versus 44 ± 5% for plasma stored platelets (p<0.01) ( Table 1 ). With the 9to 18-day PAS storage studies, the guidelines for using paired 1-day plasma stored or "fresh" platelets as controls were established. There were no significant differences in post-storage results for 9-day PAS stored compared to 1-day plasma stored platelets. For PAS platelets stored for ≥13 days, there were significant decreases in both platelet recoveries and survivals compared to 1-day stored or fresh platelets. PAS stored platelet recoveries and survivals declined progressively over storage times of 5 to 18 days ( Figures 1A and 1B to CPP (PVC with tributyl citrate plasticizer). When platelets were stored for 15 days in the CLX versus the CPP bags, viability was significantly decreased; i.e., platelet recoveries were 57 ± 5% versus 24 ± 7% (p<0.001) and survivals were 3.4 ± 0.5 days versus 2.2 ± 0.4 days (p=0.004), respectively.
In Vitro Data
Storage intervals of 14 days or more showed unacceptable decreases in platelet counts compared to day 1 of 10% to 20% ( Table 2 ). Glucose concentrations were very low even with only 9 days of storage. Morphology scores were relatively stable, while Annexin V binding increased and ESC values decreased over storage time. HSR values also decreased but not until ≥ 14 days of storage. Post-storage pH's were stable, and none were less than 7.0.
Spectra Platelets
In Vivo Data
These studies were done before the FDA guidelines for platelet storage were established, and a variety of controls were used. PAS versus plasma-stored platelets at 7 days gave platelet recoveries of 37 ± 8% versus 52 ± 4%, respectively (p=0.05), while platelet survivals were not significantly different ( Table 1 ). Eight and 9-day PAS stored platelets were compared to 5-day plasma stored platelets, and both the PAS recoveries and survivals were significantly less for all comparisons (p<0.05). There were progressive decreases in both platelet recoveries and survivals over storage time (Figures 1A and 1B) . Studies were not extended beyond 9 days as platelet recoveries averaged only 24 ± 6% and survivals 3.2 ± 1.1 days.
Because the results of the Spectra platelets in PAS were so inferior to the Haemonetics platelets after only 9 days (Table 1) , Spectra platelets from 6 subjects were stored for 13 days, half in a Terumo BCT storage bag [PVC with n-Butyryl tri-n-hexyl citrate (BTHC) as the plasticizer], and half in a Haemonetics CLX bag. This experiment was done to determine if the decreased viability of the Spectra platelets in PAS was due to the collection method or the storage bag. Recoveries and survivals of the platelets stored in the Terumo BCT and Haemonetics bags were 40 ± 5% and 41 ± 7% (p=0.89) and survivals were 2.2 ± 0.5 and 4.9 ± 0.8 days (p=0.06), respectively. These data suggest that at least some of the differences in results between the two systems may be related to the storage bag.
In Vitro Data
As with the Haemonetics data, by 9 days of storage, there is almost no residual glucose ( Table 2 ). Morphology scores were relatively stable between 5 and 13 days of storage, Annexin V binding increased, and ESC and HSR decreased over storage time.
Trima Platelets
In Vivo Data
To further explore the effects of the collection method, we evaluated the Trima system whose collection method differs from the Spectra system. 7,8 As the survival of Spectra platelets differed from Haemonetics by 7 days (Table 3) , we evaluated Trima platelets stored for 7, 9, and 13 days compared to "fresh" platelets. There were no differences between the Spectra and Trima systems at any storage time (Table 1 and Figures 1A and 1B) . Based on the improved results when Spectra platelets were stored in Haemonetics bags, Trima platelets were stored in Haemonetics bags for 9 days with significant improvements compared to Terumo BCT bags; i.e., recoveries averaged 44 ± 4% versus 29 ± 7%, p=0.05, and survivals averaged 5.0 ± 0.2 days versus 3.4 ± 0.6 days, p=0.01, respectively (Table 1 ). However, compared to 9-day Haemonetics platelets, Trima survivals in Haemonetics bags were still less (p= 0.01) ( Table 3 ).
In Vitro Data
Because the Trima platelets were stored for only 7 and 9 days, neither trends in the data nor differences from the Spectra platelets could be determined (Table 2 ).
However, the results appeared better when the platelets were stored for 9 days in Haemonetics versus Terumo bags.
Viability Comparisons Between PAS-Stored Haemonetics, Spectra, and Trima
Platelets
At 7 days, the recoveries of the Haemonetics, Spectra, and Trima stored platelets were not significantly different, while survivals were better for Haemonetics compared to Spectra platelets (p=0.05) but not for Trima platelets (p=0.74) ( Table 3) . At 9 days, Haemonetics recoveries and survivals were significantly better than both the Spectra and Trima platelets (p=0.007 and 0.03, respectively), and survivals (p=0.05 and 0.006, respectively). At 13 days, Haemonetics recoveries did not differ from Spectra, but survivals were significantly better (p=0.002).
When Trima and Spectra platelets were stored in Haemonetics bags for 9 or 13 days, respectively, platelet recoveries were not different than similarly stored Haemonetics platelets. However, platelet survivals were significantly less for Trima stored platelets at 9 days (p=0.01) but not for 13-day stored Spectra platelets.
Maximum Storage Duration Of Platelets That Meet FDA Post-Storage Viability
Guidelines
For Haemonetics platelets stored for 9, 13, and 14 days, comparisons were made to 1 day platelets and for 15-, 17-and 18-day storage to fresh platelets. For the Spectra data, no subjects had control platelets stored for either 1 day or fresh. For the Trima 7and 9-day stored data, comparisons were made to "fresh" platelets. The data show that platelet recoveries met the FDA's LCL of ≥ 66% and ≥ 58% of control criteria for 7 days for Trima-stored platelets (Figures 2A and B ). For Trima platelets stored for 9 days in Haemonetics CLX bags, the LCL for recoveries were 67% and for survivals were 54%. At 13 days of storage, the LCL for Haemonetics platelets were 65% for recoveries and 55% for survivals.
Effects Of Storage Volume, Platelet Concentration, Total Platelets, And Post-
Storage pCO 2 , pO 2 , And Glucose On Post-Storage pH
There were 12 Spectra or Trima platelets stored for 7 to 13 days in Terumo BCT bags that had post-storage pH's of ≤ 6.4. Ten of these units were transfused and recoveries averaged 18 ± 16% and survivals 1.8 ± 0.7 days (see legend to Table 1 for more details). In contrast, the lowest post-storage pH for Haemonetics platelets during ≤ 18 days of storage was 7.0. There was no apparent relationship between storage volume, platelet concentration, total platelet count or post-storage pCO 2 or pO 2 values, and post-storage pH ( Figure 3A , 3B, 3C, 3D, and 3E, respectively). All of the Terumo BCT platelets with low pH's had very low to absent residual glucose levels ( Figure 3F ).
However, several other Terumo BCT and Haemonetics collections had similar low glucose levels with no effect on pH.
Comparisons Of Post-Storage Platelet Recoveries And Survivals To Post-Storage In Vitro Results
For both stored platelet recoveries and survivals, there are significant correlations with total platelet count of the product, storage volume, morphology score, glucose, Annexin V binding, ESC, HSR, pCO 2 and pO 2 (all p<0.05) ( Figures 4A and 4B) .
DISCUSSION
There is known to be a fair amount of heterogeneity in platelet recoveries and survivals among normal subjects. 17 A recent study has further documented this heterogeneity, and, importantly, has demonstrated the reproducibility of fresh recoveries and survivals in the same subject. 18 Murphy 19 suggested that each subject serve as his/her own control by comparing their "fresh" platelet recoveries and survivals to their post-storage data, and the FDA has adopted this strategy for assessing post-storage platelet quality. 6 We have previously evaluated plasma-stored Haemonetics or Spectra collected platelets for 5 to 8 days, and platelet recoveries and survivals were not significantly different between the two systems. 20 With the plasma studies as background, we determined how long platelets could be stored in a PAS. Plasmalyte was selected as it was FDA licensed for intravenous use, it had previously been used for platelet storage, and no FDA-licensed PAS solutions were currently available. 21-26 Unfortunately, many of our studies were completed before the FDA's post-storage viability criteria were formulated, and so a variety of control platelets were used. Because there was little, if any, difference between 1-day stored and fresh platelet viabilities (Table 1) , if either of these platelets were used as controls, FDA post-storage viability criteria were evaluated for the test PAS platelets.
As there were no differences in 7-day Haemonetics-stored platelet recoveries or survivals with PAS concentrations between 50% to 82%, we used a target PAS concentration of 80%. The Haemonetics platelets were close to meeting the FDA's LCL for platelet recoveries and survivals after storage for 13 days (Figures 2A and 2B) . In sharp contrast to the plasma platelet storage studies where the Haemonetics and Spectra systems gave the same results, the Spectra PAS platelets had similar recoveries compared to Haemonetics but survivals were significantly less (p=0.05) after storage for only 7 days, and by 9 days, all the results were significantly less for the Spectra platelets ( Table   3 ).
The discrepant results could be due to the different methods used to process the platelets for PAS storage; i.e., hyperconcentration of the platelets with Spectra and resuspension in PAS versus platelet elutriation with PAS for the Haemonetics platelets.
The hyperconcentration may have resulted in platelet damage, and so we evaluated the Trima system which uses a different collection system and hyperconcentration method. 8, 12, 13 Unfortunately, there were no differences in post-storage platelet viability regardless of the Terumo BCT system that was used (Tables 1 and 3 and Figures 1A and   1B ).
The next question was whether the storage bag made a difference. The Haemonetics CLX bag is composed of PVC plastic with TOTM plasticizer. Haemonetics stopped manufacturing the CLX bags and, for 8 of the 11 15-day storage studies, a CPP bag composed of PVC plastic with a tributyl citrate plasticizer was used. Average recoveries for CLX versus CPP stored platelets were 56 ± 3% versus 24 ± 2% (p≤0.001) and survivals 3.7 ± 0.4 days versus 2.2 ± 0.2 days (p=0.004), respectively. Both the Terumo BCT systems use the same PVC bag with N-butyryl-tri-n-hexyl citrate (BTHC) plasticizer; i.e., the same plasticizer as in the Haemonetics CPP bags. These data may suggest the plasticizer might have a substantial effect on post-storage platelet viability when platelets are stored in PAS but not in plasma. Certainly, red cell storage studies showed the DEHP plasticizer helps maintain red cell viability during storage. 27,28 In vitro platelet assays suggest that the storage bag 29-32 and even the method of bag sterilization 33 may affect platelet quality during storage. When Terumo BCT platelets were stored in Haemonetics CLX bags, there were clear improvements in post-storage platelet viability, but the results may still not be as good as Haemonetics platelets stored in Haemonetics CLX bags (Table 3 ).
Additional evidence that the storage bag could be a problem was the frequency with which pH values fell below acceptable levels during storage with the Terumo BCT but not with Haemonetics platelets (Tables 1 and 2 ). Twelve Terumo BCT collections had pH values of <6.4, and, of the 10 injected, platelet recoveries averaged 18 ± 16% and survivals 1.8 ± 0.7 days (Table 1 ). In contrast, even though the Haemonetics platelets had higher cell counts because they were not leukoreduced compared to the in-process leukoreduced Terumo BCT platelets, all pH's were above 7.0 for ≤ 18 days of storage.
However, even when Haemonetics platelets were stored in CPP bags for 15 days, the lowest post-storage pH was 7.5, suggesting that the collection method plus the storage bag may be producing the low pH. There was no relationship between platelet volume, platelet concentration, total platelet count, or post-storage pCO 2 or pO 2 , and post-storage pH regardless of the storage conditions ( Figures 3A, B , C, D, and E). All of the Terumo BCT collections that had low pH's had low to absent residual glucose at the end of storage, while the residual glucose concentration did not appear to effect pH values for Haemonetics collected platelets and for some of the Terumo BCT collections ( Figure 3F ).
These data suggest that the Haemonetics bags allow the platelets to metabolize the acetate in the PAS to maintain pH better than platelets collected and stored in Terumo studies have suggested that enough plasma must be present during platelet storage to maintain glucose levels, 35,36 while others have indicated that residual glucose is not required. 37,38 Our studies have indicated that, depending on the storage conditions (mainly the storage bag), acetate can substitute for glucose to maintain platelet viability.
There were significant correlations between most of the in vitro assays and both platelet recoveries and survivals at the end of storage (all p<0.05) ( Figures 4A and B) . stable thrombocytopenic patients were given 4 to 12 day PAS stored pooled buffy-coat platelets, and the patients had good increments but shortened survivals.
There were several weaknesses of our studies. The studies were done sequentially and not randomized, the apheresis collections were done outside manufacturers guidelines, and Plasmalyte was used for elutriation of platelets on the Haemonetics system and it is also not a licensed storage solution. (6) Our data are the best results yet reported in the literature for extended stored platelets and demonstrate that platelet viability is better maintained in vitro than in vivo.
Specifically, fresh radiolabeled autologous platelet survivals in the 38 normal subjects in our studies averaged 8.2 ± 0.2 days, while platelets could be stored in vitro for 13 days with a residual in vivo lifespan of 4.6 ± 0.3 for a combined in vitro/in vivo lifespan of For personal use only. on October 24, 2017. by guest www.bloodjournal.org From almost 18 days fully 9 days longer than in vivo (Table 1) . This in vivo versus in vitro difference may be related to an ongoing "work related" platelet utilization to maintain vascular integrity. Further studies are needed to confirm our results and to determine how to reduce any collection injury, identify the best PAS, the optimal PAS concentration, and the storage bag. These parameters may all interact in ways we do not yet understand. We also recognize that either pathogen-reduction or a sensitive and specific point of release bacterial assay will be needed before the FDA will license extended stored platelets. Data for Haemonetics stored platelets in CLX bags are given as closed circles ( ), for Spectra stored platelets as closed triangles ( ), for Trima stored platelets as closed squares ( ). All data are given for platelets stored in each system's own bags.
TABLE 2 IN VITRO ASSAYS OF HAEMONETICS, SPECTRA, AND TRIMA APHERESIS PLATELETS STORED IN PAS H A E M O N E T I C S A P H E R E S I S P L A T E L E T
Data are given as average ±1 S.E.
Figure 2 Stored Platelet Recoveries and Survivals As A Percentage Of Control
Platelets (Fresh or 1 Day Plasma Stored Platelets).
Figure 2A
Stored Platelet Recoveries Compared To Control Platelets.
Figure 2B
Stored Platelet Survivals Compared To Control Platelets.
Shown are the 2-sided, lower 95% confidence limits (LCL) for the mean difference between the stored platelets and the proportion of the fresh or 1 day plasma platelets (control platelets) specified by the FDA criteria. The LCLs are a function of both the means and the standard deviations of these differences. 
Figure 3A
Post-Storage pH Versus Storage Volume.
Figure 3B
Post-Storage pH Versus Platelet Concentration.
Figure 3C
Post-Storage pH Versus Total Platelet Count.
Figure 3D
Post-Storage pH Versus Post-Storage pCO 2 .
Figure 3E
Post-Storage pH Versus Post-Storage pO 2 . 
Figure 3F
Figure 4A
Post-Storage Platelet Recoveries Versus In Vitro Measurements.
Figure 4B
Post-Storage Platelet Survivals Versus In Vitro Measurements. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Figure 3E For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
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